First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results.

JSON

Di Giacomo AM, Santangelo F, Amato G, Simonetti E, Graham J, Lahn MMF, van der Veen LA, Johnson Z, Pickering CA, Durini M, Tan Z, Tadepally L, Brodin P, Occhipinti M, Simonelli M, Carlo-Stella C, Santoro A, Spiliopoulou P, Evans TRJ, Maio M

J Clin Oncol 40 (16_suppl) 3107-3107 [2022-06-01; online 2022-06-01]

DOI 10.1200/jco.2022.40.16_suppl.3107

Crossref 10.1200/jco.2022.40.16_suppl.3107